Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The investigators developed 18F-IRS as a targeted molecular imaging agent for noninvasive and repeatable detecting EGFR-activating mutational status.
The goal of investigators were to evaluate the use of 18F-IRS as a novel PET/CT radiotracer to monitor EGFR-activating mutational status and identify EGFR-TKIs benefit NSCLC patients. the investigators want to evaluated the use of 18F-IRS in lung cancer imaging in adult NSCLC patients with different EGFR mutational status of primary and metastatic cancers.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 18F-IRS : EGFR+ Patients | Experimental | Patients in this group had EGFR-activating mutant tumors and did not receive any treatment before this study. |
|
| 18F-IRS :post-TKI EGFR+ Patients | Experimental | Patients with EGFR-activating mutant tumors were receiving EGFR-TKIs during this study . |
|
| 18F-IRS:post-chemo EGFR+ | Experimental | 18F-IRS:post-chemo EGFR+ Patients with EGFR-activating mutant tumors were receiving chemotherapy during this study. |
|
| 18F-IRS:EGFR wild type | Experimental | Patients in this group had EGFR wild-type tumors and did not receive any treatment before this study. |
|
| 18F-IRS:post-chemo EGFR wild type | Experimental | Patients in this group had EGFR wild-type tumors and were receiving chemotherapy during this study. |
|
| 18F-IRS:unknown EGFR mutational status |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| 18F-IRS | Radiation | According to experiment, 18F-IRS was non-toxic and stable in serum. |
|
| Measure | Description | Time Frame |
|---|---|---|
| tumor SUVmax value of 18F-IRS PET/CT Imaging | To quantify the accumulation, a volume of interest using a 3-D sphere, was placed over the primary lung tumor, lymph nodes and distant metastases avoiding necrosis, blood vessels and normal lung tissue as much as possible on a workstation (Advantage Workstation 4.6; GE Healthcare). The maximum standard uptake value (SUVmax) normalized to body weight (kBq/mL) was calculated within the region of interest. | at time of imaging |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Baozhong Shen, M.D. | The Fourth Hospital of Harbin Medical University | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| TOF-PET/CT/MR center of the Fourth Hospital of Harbin Medical University | Harbin | Heilongjiang | 150028 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Experimental |
Patients without the EGFR mutational status measurement results and did not receive any treatments were classified in this group |
|